Subcutaneous anakinra in the management of refractory MIS-C in France.
Fiche publication
Date publication
février 2024
Journal
Frontiers in pediatrics
Auteurs
Membres identifiés du Cancéropôle Est :
Pr HUET Frédéric
Tous les auteurs :
Dusser P, Belot A, Bajolle F, Kevorkian-Verguet C, Meinzer U, Huet F, Tiriau S, Kone-Paut I
Lien Pubmed
Résumé
Multisystemic inflammatory syndrome in children (MIS-C) is a therapeutic emergency and can lead to myocardial dysfunction (17%-75%) and heart failure (52%-53%). Intravenous immunoglobulins (IVIG) and corticosteroids (CST) have been validated for the management of this condition. Recent reports suggest that an interleukin-1 (IL-1) receptor antagonist, namely anakinra, may be a valuable add-on to the 2019 novel coronavirus disease (COVID-19) treatment for refractory patients. The purpose of this study was to describe the clinico-biological characteristics of patients treated with anakinra as well as the efficacy and safety of subcutaneous anakinra therapy in this condition.
Mots clés
COVID-19, anakinra, epidemiology, interleukin-1, multisystem inflammatory syndrome in children, myocarditis
Référence
Front Pediatr. 2024 02 23;12:1270878